Hepatitis C patients' self-reported adherence to treatment with pegylated interferon and ribavirin

被引:30
|
作者
Weiss, J. J. [1 ]
Bhatti, L. [2 ]
Dieterich, D. T. [3 ]
Edlin, B. R. [4 ]
Fishbein, D. A. [3 ]
Goetz, M. B. [5 ,6 ]
Yu, K. [7 ]
Wagner, G. J. [8 ]
机构
[1] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA
[2] AIDS Healthcare Fdn, Los Angeles, CA USA
[3] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA
[4] Cornell Univ, Weill Med Coll, Ctr Study Hepatitis C, New York, NY 10021 USA
[5] VA Greater Los Angeles Healthcare Syst, Dept Med, Infect Dis Sect, Los Angeles, CA USA
[6] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[7] W LA Kaiser Permanente, Dept Infect Dis, Los Angeles, CA USA
[8] RAND Corp, Hlth Unit, Santa Monica, CA USA
关键词
D O I
10.1111/j.1365-2036.2008.03718.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Prior research on adherence to hepatitis C treatment has documented rates of dose reductions and early treatment discontinuation, but little is known about patients' dose-taking adherence. Aim To assess the prevalence of missed doses of pegylated interferon and ribavirin and examine the correlates of dose-taking adherence in clinic settings. Methods One hundred and eighty patients on treatment for hepatitis C (23% co-infected with HIV) completed a cross-sectional survey at the site of their hepatitis C care. Results Seven per cent of patients reported missing at least one injection of pegylated interferon in the last 4 weeks and 21% reported missing at least one dose of ribavirin in the last 7 days. Dose-taking adherence was not associated with HCV viral load. Conclusions Self-reported dose non-adherence to hepatitis C treatment occurs frequently. Further studies of dose non-adherence (assessed by method other than self-report) and its relationship to HCV virological outcome are warranted.
引用
收藏
页码:289 / 293
页数:5
相关论文
共 50 条
  • [31] Vitiligo associated with pegylated interferon and ribavirin treatment of patients with chronic hepatitis C: A case report
    Tomasiewicz, K
    Modrzewska, R
    Semczuk, G
    ADVANCES IN THERAPY, 2006, 23 (01) : 139 - 142
  • [32] Effect of pegylated interferon and ribavirin used for treatment of chronic hepatitis C patients on semen parameters
    Mostafa, Hamdy Mahfouz
    Eid, Khaled Abdel Azeem
    Maguid, Mona Mohamed Abdel
    Elsaid, Abdel Rahman Abdel Hamid
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 210 - 210
  • [33] Treatment of chronic hepatitis C with pegylated interferon plus ribavirin in HIV-infected patients
    Romero, M
    Perez-Olmeda, M
    Garcia-Samaniego, J
    Gonzalez, J
    Castro, A
    Arribas, JR
    Pedreira, J
    Soriano, V
    JOURNAL OF HEPATOLOGY, 2002, 36 : 107 - 107
  • [34] Frequency of Erectile Dysfunction in Patients Receiving Pegylated Interferon and Ribavirin for the Treatment of Chronic Hepatitis C
    Kumar, Prem
    Das, Chaman
    Raja, Kapeel
    Nadeem, Muhammad Arif
    Akhtar, Muhammad Nasim
    Rani, Shabnam
    JOURNAL OF PHARMACEUTICAL RESEARCH INTERNATIONAL, 2021, 33 (22B)
  • [35] Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment
    Neukam, K.
    Mira, J. A.
    Gilabert, I.
    Claro, E.
    Vazquez, M. J.
    Cifuentes, C.
    Garcia-Rey, S.
    Merchante, N.
    Almeida, C.
    Macias, J.
    Pineda, J. A.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2012, 31 (06) : 1225 - 1232
  • [36] Treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon and ribavirin.
    Samuel, D
    HEPATOLOGY, 2003, 38 (04) : 531A - 531A
  • [37] Vitiligo associated with pegylated interferon and ribavirin treatment of patients with chronic hepatitis C: A case report
    Krzysztof Tomasiewicz
    Romana Modrzewska
    Grażyna Semczuk
    Advances in Therapy, 2006, 23
  • [38] Safety and efficacy of pegylated interferon α-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia
    Harmatz, Paul
    Jonas, Maureen M.
    Kwiatkowski, Janet L.
    Wright, Elizabeth C.
    Fischer, Roland
    Vichinsky, Elliott
    Giardina, Patricia J.
    Neufeld, Ellis J.
    Porter, John
    Olivieril, Nancy
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 (08): : 1247 - 1251
  • [39] Efficacy and Safety of Pegylated Interferon Combined with Ribavirin for the Treatment of Older Patients with Chronic Hepatitis C
    Huang, Chung-Feng
    Yang, Jeng-Fu
    Dai, Chia-Yen
    Huang, Jee-Fu
    Hou, Nai-Jen
    Hsieh, Ming-Yen
    Lin, Zu-Yau
    Chen, Shinn-Cherng
    Hsieh, Ming-Yuh
    Wang, Liang-Yen
    Chang, Wen-Yu
    Chuang, Wan-Long
    Yu, Ming-Lung
    JOURNAL OF INFECTIOUS DISEASES, 2010, 201 (05): : 751 - 759
  • [40] Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment
    K. Neukam
    J. A. Mira
    I. Gilabert
    E. Claro
    M. J. Vázquez
    C. Cifuentes
    S. García-Rey
    N. Merchante
    C. Almeida
    J. Macías
    J. A. Pineda
    European Journal of Clinical Microbiology & Infectious Diseases, 2012, 31 : 1225 - 1232